HealthEquity Research and Development Expenses 2014-2024 | HQY

HealthEquity research and development expenses for the twelve months ending July 31, 2024 were $0.226B, a 7.61% increase year-over-year.

  • HealthEquity annual research and development expenses for 2024 were $0.219B, a 13.15% increase from 2023.
  • HealthEquity annual research and development expenses for 2023 were $0.193B, a 22.88% increase from 2022.
  • HealthEquity annual research and development expenses for 2022 were $0.157B, a 26.08% increase from 2021.

HealthEquity Research and Development Expenses 2014-2024 | HQY

  • HealthEquity annual research and development expenses for 2024 were $0.219B, a 13.15% increase from 2023.
  • HealthEquity annual research and development expenses for 2023 were $0.193B, a 22.88% increase from 2022.
  • HealthEquity annual research and development expenses for 2022 were $0.157B, a 26.08% increase from 2021.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$93.4B
Cencora (COR)$48.3B
DiDi Global (DIDIY)$22.2B
Natera (NTRA)$22.1B
ICON (ICLR)$17.7B
Viatris (VTRS)$16B
Avantor (AVTR)$14.1B
Revvity (RVTY)$13.6B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.2B
BioMerieux (BMXMF)$11.9B
Medpace Holdings (MEDP)$10.5B
Charles River Laboratories (CRL)$10B
Doximity (DOCS)$9B
Sonic Healthcare (SKHHY)$8.9B
Bausch + Lomb (BLCO)$6.9B
Life Times (LTH)$5.1B
Organon (OGN)$3.9B
Sotera Health (SHC)$3.6B
BrightSpring Health Services (BTSG)$3.3B
Surgery Partners (SGRY)$2.9B
Concentras Parent (CON)$2.8B
PACS (PACS)$2.5B
Alignment Healthcare (ALHC)$2.3B
Ardent Health Partners (ARDT)$2.3B
Premier (PINC)$2.2B
GeneDx Holdings (WGS)$2.2B
Ryman Healthcare (RYHTY)$2B
GoodRx Holdings (GDRX)$1.9B
Teladoc Health (TDOC)$1.8B